ArticlePublished 10 Apr 2011
Bioavailability of Two Oral-Suspension Formulations of a Single Dose of Nitazoxanide 500 mg: An Open-Label, Randomized-Sequence, Two-Period Crossover, Comparison in Healthy Fasted Mexican Adult Volunteers
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Nitazoxanide is an oral broad-spectrum parasiticidal agent. In Mexico, the oral powder for suspension of nitazoxanide is indicated for the treatment of antiprotozoal and anthelmintic infections in patients of 1 year or older. The aims of this study were to compare the bioavailability and to determine the bioequivalence of a test and reference formulation of oral nitazoxanide 500 mg, administered as a suspension, and to generate data regarding the oral bioavailability of this drug on the Mexican population. This single-dose, randomized-sequence, open-label, 2-period crossover study was conducted on a total of 26 Mexican adult subjects of both genders, with a 1-week washout period. Study formulations were administered after a 10-hour overnight fast. For pharmacokinetic analysis, blood samples were drawn at 0 (baseline), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10 and 12 hours after administration. Plasma concentrations of tizoxanide (active metabolite of nitazoxanide) were determined using HPLC coupled to a mass spectrometry (MS/MS). The test and reference formulations were to be considered bioequivalent if the 90% CIs for the geometric mean test/reference ratios were within a predetermined range of 80% to 125%. The estimated pharmacokinetic parameters of tizoxanide for the reference (Daxon®) and test (Paramix®) formulations were: Cmax (10.40±2.99 μg/ml, 10.73 ± 3.45 μg/ml); AUC0–t (39.57 ± 15.89 µg•h /ml, 43.31 ± 19.13 µg•h / ml); and AUC0–∞ (40.93 ± 16.05 µg•h /ml, 45.00 ± 19.63 µg•h /ml), respectively. The 90% CIs for the geometric mean ratios of Cmax, AUC0–t, and AUC0–∞ were: 94.58%-110.21%, 100.43%-116.22%, and 101.00%-116.43%, respectively, the within-subject %CV values were 16.23, 15.49 and 15.05, respectively. All the power values were 100%. In this study a single dose of the test formulation met the regulatory requirements to assume bioequivalence, based on the rate and extent of absorption.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectPharmaceutical Sciences